Zobrazeno 1 - 10
of 25
pro vyhledávání: ''
Autor:
Philipp B. Staber, Peter Bettelheim, Christian Sillaber, Gabriele Stefanzl, Dubravka Smiljkovic, Daniela Berger, Georg Greiner, Peter Valent, Karin Bauer, Wolfgang R. Sperr, Ana-Iris Schiefer, Susanne Gamperl, Ilse Schwarzinger, Renate Thalhammer, Gregor Hoermann, Paul Knöbl, Christoph Kornauth
Publikováno v:
Neoplasia: An International Journal for Oncology Research, Vol 23, Iss 12, Pp 1183-1191 (2021)
Neoplasia (New York, N.Y.)
Neoplasia (New York, N.Y.)
During progression of myeloid neoplasms, the basophil compartment may expand substantially and in some of these patients, a basophilic leukemia is diagnosed. In patients with Ph-chromosome+ chronic myeloid leukemia, acceleration of disease is typical
Autor:
Vasantha Lakshmi Gali, Mingzhi Zhang, Xiaosheng Fang, Yong Li, Fredrick B. Hagemeister, Donna M. Weber, Sheeba K. Thomas, Hans C. Lee, Zijun Y. Xu-Monette, Dahlia Sano, Manman Deng, Robert Z. Orlowski, Ken H. Young, Feng Zhu, Yingjun Wang
Publikováno v:
Neoplasia: An International Journal for Oncology Research, Vol 23, Iss 4, Pp 361-374 (2021)
Neoplasia (New York, N.Y.)
Neoplasia (New York, N.Y.)
Waldenström macroglobulinemia (WM) is a distinct type of indolent lymphoplasmacytic lymphoma (LPL) with a high frequency of MYD88L265P mutation. Treatment for WM/LPL is highly variable in clinic and ibrutinib (a Bruton tyrosine kinase inhibitor, BTK
Autor:
Masaru Suzuki, Satoshi Oizumi, Eiki Kikuchi, Kenya Kanazawa, Hisashi Tanaka, Kaoruko Shimizu, Hiroshi Yokouchi, Ryoichi Honda, Toshiyuki Harada, Hajime Asahina, Tomoo Ikari, Kei Takamura, Tetsuya Kojima, Masao Harada, Yuka Fujita, Hiroshi Isobe, Hirotoshi Dosaka-Akita, Takahiro Ogi, Masaharu Nishimura, Fumiko Sugaya, Satoshi Konno
Publikováno v:
Lung cancer. 138:65-71
Objectives Patients with concomitant advanced non-small cell lung cancer (NSCLC) and interstitial lung disease (ILD) are excluded from most clinical chemotherapy trials because of the high risk of exacerbating the latter condition. This study prospec
Publikováno v:
ESMO Open
Primary diffuse large B-cell (DLBCL) lymphoma of the central nervous system (CNS) (PCNSL) is a new lymphoma entity, recognized by the 2017 WHO classification of hematopoietic and lymphoid tumors. Unlike systemic DLBCL, the use of anthracycline-based
Autor:
Laura Wormser, Claus Hellerbrand, Anja-Katrin Bosserhoff, Valerie Fritz, Peter Dietrich, Anne Gaza
Publikováno v:
Neoplasia: An International Journal for Oncology Research, Vol 21, Iss 3, Pp 257-268 (2019)
Neoplasia (New York, N.Y.)
Neoplasia (New York, N.Y.)
Inhibition of the RAS-RAF-ERK-pathway using sorafenib as a first-line and regorafenib as a second-line treatment approach is the only effective therapeutic strategy for advanced hepatocellular carcinoma (HCC). Recent studies suggest that wild-type KR
Autor:
Hyun Yang Yeo, Kyung Hae Jung, Yongjun Cha, Sun-Young Kim, Moon Ki Choi, Hee Jin Chang, Seung Myung Dong, Ji Yeon Baek
Publikováno v:
Neoplasia: An International Journal for Oncology Research, Vol 21, Iss 1, Pp 146-155 (2019)
Neoplasia (New York, N.Y.)
Neoplasia (New York, N.Y.)
Aberrant promoter methylation plays a vital role in colorectal carcinogenesis. However, its role in treatment responses is unclear, especially for metastatic disease. Here, we investigated the association between promoter methylation and treatment ou
Autor:
A. Sánchez Gastaldo, J. Salvador Boffil, A. Falcon Gonzalez, P. Estévez Garcia, I. Sánchez Simón, M. Ruiz Borrego
Publikováno v:
Cancer Treatment and Research Communications, Vol 27, Iss, Pp 100314-(2021)
HER2-positive metastatic breast cancer is an aggressive disease with a limited number of treatment options. In the last 15 years, new drugs such as trastuzumab, pertuzumab, lapatinib or trastuzumab emtansine (TDM-1) have sprouted for these patients.
Autor:
Jing Wang, Sheryl Coppola, Kristian M. Bowles, Al-Ola Abdallah, Emma Arriola, Orlando F. Bueno, Maria-Victoria Mateos, Gudrun Mander, Lura Morris, Jeremy A. Ross, Cristina Gasparetto
Publikováno v:
Digital.CSIC. Repositorio Institucional del CSIC
instname
instname
© 2021 The Authors.
[Background]: Venetoclax is a selective BCL-2 inhibitor with clinical activity in relapsed/refractory multiple myeloma (RRMM). Combinations of venetoclax with agents that have complementary mechanisms of action may improve v
[Background]: Venetoclax is a selective BCL-2 inhibitor with clinical activity in relapsed/refractory multiple myeloma (RRMM). Combinations of venetoclax with agents that have complementary mechanisms of action may improve v
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c70ff222b62d396ee5c5c4116539a632
http://hdl.handle.net/10261/261010
http://hdl.handle.net/10261/261010
Autor:
Belinda L. Sun, Xiaoguang Sun, Joe G.N. Garcia, Taylor Gregory, Amit M. Algotar, Sara M. Camp, Nancy Casanova, Alexander N. Garcia, Vivian Reyes Hernon, Radu C. Oita, Anne E. Cress
Publikováno v:
EBioMedicine, Vol 61, Iss, Pp 103059-(2020)
EBioMedicine
EBioMedicine
Background There remains a serious need to prevent the progression of invasive prostate cancer (PCa). We previously showed that secreted extracellular nicotinamide phosphoribosyltransferase (eNAMPT) is a multifunctional innate immunity regulator via
Autor:
Loick Vidot, Julien Taieb, Irfan Cicin, Ahmet Ozet, Martin Becquart, Fabienne Portales, Timothy J. Price, Chiara Cremolini, Dan Atlan, Jean-Marc Phelip, Jean-Baptiste Bachet, Nadjat Mounedji, Eric Van Cutsem, Alfredo Falcone, Lucjan Wyrwicz
Publikováno v:
Open
Open, 2020, 5 (3), pp.e000698. ⟨10.1136/esmoopen-2020-000698⟩
ESMO Open
Open, J. Wiltenburg, 2020, 5 (3), pp.e000698. ⟨10.1136/esmoopen-2020-000698⟩
ESMO Open, Vol 5, Iss 3 (2020)
Open, 2020, 5 (3), pp.e000698. ⟨10.1136/esmoopen-2020-000698⟩
ESMO Open
Open, J. Wiltenburg, 2020, 5 (3), pp.e000698. ⟨10.1136/esmoopen-2020-000698⟩
ESMO Open, Vol 5, Iss 3 (2020)
BACKGROUND: In RECOURSE (, trifluridine/tipiracil significantly improved overall survival and progression-free survival (PFS) versus placebo in patients with pretreated metastatic colorectal cancer (mCRC). PRECONNECT was designed to further character
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0aa2d1c5f07241302eb7c6faa34b0d96
https://lirias.kuleuven.be/handle/123456789/655767
https://lirias.kuleuven.be/handle/123456789/655767